Article Text
Statistics from Altmetric.com
As England waits with bated breath for the government's decision whether to fund Cervarix (the bivalent vaccine currently used in the national vaccination programme) or quadrivalent Gardasil, we publish two papers exploring the impact of genital warts in England. This is a difficult area to study, since patients with genital warts may present in a variety of settings, and be referred between them. In an unlocked article, Desai et al1 estimate diagnosed incidence in general practice using a large primary care database, and in genitourinary medicine specialist clinics. With an estimated 1.3% of cases requiring hospital care, the authors conclude that morbidity costing £16.8M per year could be largely prevented by a change in vaccine. Readers may be aware that a survey of members of British Association for Sexual Health and HIV Research showed that 61% with …